IMS Health Holdings (IMS) has risen sharply, recording gains of 6.03% in the past 4 weeks. However, the stock has corrected -1.3% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 4.95% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 1.13% and the 50-Day Moving Average is 8.81%. IMS Health Holdings (NYSE:IMS): On Fridays trading session , Opening price of the stock was $29.84 with an intraday high of $29.84. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $29.445. However, the stock managed to close at $29.54, a loss of 0.64% for the day. On the previous day, the stock had closed at $29.73. The total traded volume of the day was 586,078 shares.
The company Insiders own 2.5% of IMS Health Holdings shares according to the proxy statements. Institutional Investors own 88.94% of IMS Health Holdings shares. Also, Equity analysts at the Brokerage firm Wells Fargo downgrades its rating on IMS Health Holdings (NYSE:IMS). The rating major has initiated the coverage with market perform rating on the shares. Earlier, the shares were rated a Outperform by the brokerage firm. The rating by the firm was issued on May 12, 2016.
IMS Health Holdings, Inc. (IMS) is an information and technology services company that provides solutions to its clients in the healthcare industry. The Company has its presence in over 100 countries. The Companys data set contains over 10 petabytes of data and over 500 million patient records. The Company serves healthcare organizations and life science companies, including pharmaceutical, biotechnology, consumer health and medical device manufacturers, as well as distributors, providers, payers, government agencies, policymakers, researchers and the financial community. The Companys principal offerings include national information offerings, sub-national information offerings, workflow analytics, real-world evidence (RWE) solutions, technology and applications and clinical solutions.